Lorus Receives Patent Allowances to Protect Novel Anticancer Drug in Phase II Trials

Lorus Therapeutics has announced that its wholly owned subsidiary GeneSense Technologies has received notice from the European Patent Office of its intention to grant the GeneSense application for a patent of its novel antisense drug GTI-2040.

Lorus also announced that GeneSense has received a patent issued by the Canadian Patent Office for GTI-2040.

Currently, development of GTI-2040 is being supported under a clinical trials agreement with the U.S. National Cancer Institute (NCI). Given the potential for GTI-2040 to improve the efficacy of a number of chemotherapies, for a range of indications, clinical trials conducted under the NCI-CTEP program involve combination therapy against non-small cell lung cancer, breast cancer, colorectal cancer, acute myeloid leukemia, prostate cancer and a variety of solid tumors.